Filing Details
- Accession Number:
- 0001562180-24-005658
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-08 17:57:30
- Reporting Period:
- 2024-07-05
- Accepted Time:
- 2024-07-08 17:57:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1560241 | G1 Therapeutics Inc. | GTHX | Pharmaceutical Preparations (2834) | 263648180 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1706853 | Rajesh Malik | 700 Park Offices Drive, Suite 200 Research Triangle Park NC 27709 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-07-05 | 2,475 | $2.51 | 159,312 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the Reporting Person.
- The price represents the weighted average price with a low of $2.47 and a high of $2.545. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Represents (i) 87,450 shares of common stock; (ii) 1,375 RSUs from award granted on January 4, 2021; (iii) 4,500 RSUs from award granted on January 3, 2022; (iv) 11,187 RSUs from award granted on January 3, 2023; (v) 17,500 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.